5th Annual ACDM Symposium on AI

QFINITY is on site at the 5th Annual ACDM Symposium on Artificial Intelligence in Clinical Trials, taking place on 23–24 June 2026 in London, UK.

The symposium brings together professionals from pharma, CROs and technology providers to discuss the current and future role of artificial intelligence in clinical trials. The programme focuses on practical insights, real-life case studies, expert discussions and networking opportunities around topics such as agentic AI, AI strategy, real-world deployment journeys and the next phase of AI in clinical trials.

QFINITY is represented by Marcus Schwabedissen, COO and consultant at QFINITY. With his extensive background in GxP-regulated life science and IT environments, computerized system validation, IT quality management, risk management and regulatory compliance, Marcus contributes a practical perspective on the responsible and compliant use of AI-enabled systems in regulated environments.

In addition, Marcus Schwabedissen co-leads the roundtable discussion “Turning AI into Impact: Real-World Applications in Clinical Data Management” together with Jennifer Duff and Tim Armitage. The session focuses on where AI is already creating value in clinical data management, where implementation remains challenging, and which organizational, technical and regulatory conditions are needed to turn AI potential into measurable impact.

For QFINITY, the symposium is an important opportunity to exchange ideas with international experts, discuss practical approaches to AI governance, validation, data integrity and lifecycle management, and explore how AI can be implemented in a controlled, risk-based and audit-ready manner.

Meet us on site in London.
We look forward to discussing how AI-enabled solutions can be applied responsibly and effectively in regulated clinical and life science environments.

For more information visit the ACDM Website.